Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1 blockade are rational approaches to prevent relapse. Here, we test CD19/2...

Descripción completa

Detalles Bibliográficos
Autores principales: Roddie, Claire, Lekakis, Lazaros J., Marzolini, Maria A. V., Ramakrishnan, Aravind, Zhang, Yiyun, Hu, Yanqing, Peddareddigari, Vijay G. R., Khokhar, Nushmia, Chen, Robert, Basilico, Silvia, Raymond, Meera, Vargas, Frederick Arce, Duffy, Kevin, Brugger, Wolfram, O’Reilly, Maeve A., Wood, Leigh, Linch, David C., Peggs, Karl S., Bachier, Carlos, Budde, Elizabeth Lihua, Lee Batlevi, Connie, Bartlett, Nancy, Irvine, David, Tholouli, Eleni, Osborne, Wendy, Ardeshna, Kirit M., Pule, Martin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646794/
https://www.ncbi.nlm.nih.gov/pubmed/36821767
http://dx.doi.org/10.1182/blood.2022018598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646794/
https://www.ncbi.nlm.nih.gov/pubmed/36821767
http://dx.doi.org/10.1182/blood.2022018598

Ejemplares similares